Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease
9th
Nov 23
Release Date: 09/11/2023 9:28am
Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease.
The first patient has been dosed in Sydney in a multi-national trial that is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK.
1. At the 2023 annual general meeting to be held on 28 November 2023, Pharmaxis shareholders will be asked to approve a change in the name of the company from Pharmaxis Ltd to Syntara Limited (ASX: SNT).
Categories: News and Media